Pre-Submission Review for Pharmacology Manuscripts: What Reviewers Expect in 2026
Pharmacology manuscripts need dose-response data, proper controls, in vivo validation, and clear therapeutic relevance. Here is what reviewers at top pharmacology journals expect.
Associate Professor, Clinical Medicine & Public Health
Author context
Specializes in clinical and epidemiological research publishing, with direct experience preparing manuscripts for NEJM, JAMA, BMJ, and The Lancet.
Readiness scan
Find out if this manuscript is ready to submit.
Run the Free Readiness Scan before you submit. Catch the issues editors reject on first read.
How to use this page well
These pages work best when they behave like tools, not essays. Use the quick structure first, then apply it to the exact journal and manuscript situation.
Question | What to do |
|---|---|
Use this page for | Building a point-by-point response that is easy for reviewers and editors to trust. |
Start with | State the reviewer concern clearly, then pair each response with the exact evidence or revision. |
Common mistake | Sounding defensive or abstract instead of specific about what changed. |
Best next step | Turn the response into a visible checklist or matrix before you finalize the letter. |
Quick answer: Pre-submission review pharmacology is most useful when the manuscript still has open risk around potency interpretation, selectivity, PK logic, or therapeutic relevance. A pharmacology paper can look impressive on first read and still fail because the dose-response story, off-target posture, or in vivo rationale is not strong enough for reviewers who know the field. The right review is a stress test of whether the compound story is specific, believable, and publication-ready. Reviewers want dose-dependent activity, selectivity evidence, exposure logic, and claims that stay proportional to what the data really show.
Check your pharmacology manuscript readiness in 1-2 minutes with the free scan.
Pre-submission review pharmacology: what reviewers screen first
Pharmacology is fundamentally about dose-response. Reviewers expect:
- complete dose-response curves (not single-concentration tests)
- IC50, EC50, or Ki values calculated from the curves
- Hill coefficients or slope factors reported
- appropriate curve-fitting methods described
- adequate number of concentrations tested (minimum 6 to 8 for a meaningful curve)
Selectivity and specificity
A compound that hits everything is not a drug candidate. Reviewers expect:
- selectivity testing against related targets (kinase panels, receptor panels, etc.)
- counterscreens ruling out nonspecific mechanisms (aggregation, membrane disruption, assay interference)
- PAINS analysis for medicinal chemistry papers (pan-assay interference compounds)
- appropriate negative controls (structurally similar inactive compounds)
In vivo validation
For papers claiming therapeutic potential, reviewers expect:
- pharmacokinetic data (Cmax, t1/2, AUC, oral bioavailability)
- efficacy in a disease-relevant animal model
- dose selection justified by PK data (not arbitrary)
- toxicity assessment at efficacious doses
- appropriate vehicle and route of administration controls
Reproducibility and statistical rigor
- biological replicates (not just technical replicates)
- sample sizes justified for the expected effect
- blinding where appropriate (especially for in vivo studies)
- statistical tests matched to the data type
- ARRIVE 2.0 guidelines followed for animal experiments
Common pharmacology desk rejection triggers
The most common reasons pharmacology manuscripts are rejected at top journals:
- Single-concentration testing. Showing activity at one concentration proves nothing about pharmacology. Reviewers expect full dose-response curves with calculated potency values. A paper that says "compound X inhibited enzyme Y at 10 micromolar" without a dose-response curve will be returned immediately.
- No selectivity data. A compound that hits everything is not a therapeutic lead. If the paper claims therapeutic potential without demonstrating selectivity against off-targets, reviewers will question whether the observed effects are specific or artifacts.
- In vivo efficacy without PK. Dosing an animal without knowing the pharmacokinetics is not pharmacology. If the paper shows in vivo efficacy, reviewers expect to see at least basic PK data (plasma levels, half-life) showing that the compound reaches the target at relevant concentrations.
- PAINS compounds not flagged. Pan-assay interference compounds (PAINS) are structural motifs known to interfere with common assay formats. If the compound contains a PAINS alert and the paper does not address it, reviewers familiar with medicinal chemistry will flag the omission.
- Overclaimed therapeutic potential. In vitro data alone does not demonstrate therapeutic utility. Claims about "potential new treatment for disease X" based on enzyme inhibition in a cell-free assay are overclaimed.
For in vitro pharmacology
- dose-response curves with IC50/EC50/Ki for all key compounds
- selectivity data against related targets
- counterscreens for assay artifacts
- mechanism of action data (binding kinetics, reversibility, competitive vs noncompetitive)
- appropriate positive and negative controls in every assay
For in vivo pharmacology
- PK data supporting dose selection
- efficacy in a disease-relevant model (not just a convenient one)
- dose-response in vivo (not just one dose)
- appropriate vehicle controls
- toxicity assessment
- ARRIVE 2.0 compliance
For all pharmacology manuscripts
- compound identity confirmed (HPLC purity, NMR, mass spec)
- compound stability assessed in assay conditions
- data deposited where applicable
- statistical methods described and appropriate
- conclusions proportional to the evidence (in vitro data alone does not prove therapeutic utility)
In our pre-submission review work
In our pre-submission review work, pharmacology manuscripts most often run into trouble when a strong-looking activity signal gets treated as if it already proves a therapeutic story. Reviewers separate those questions quickly. They want to know whether the effect is selective, whether the PK logic supports the dose, and whether the manuscript distinguishes target engagement from actual translational promise.
Our review of current pharmacology author guidance points to the same standard. Strong submissions expose dose-response logic, counterscreens, and model fit clearly enough that reviewers do not have to guess whether the compound story is real or only convenient.
Where pre-submission review helps in pharmacology
The manuscript readiness check evaluates methodology and journal fit in about 1-2 minutes. For pharmacology manuscripts, citation verification catches missing references to competing compounds or recently published drug targets.
The manuscript readiness check provides figure-level feedback, which is important for dose-response curves and pharmacology data presentations. For high-stakes submissions, Manusights Expert Review connects you with reviewers experienced in pharmacology publishing.
Pharmacology risk matrix
Pharmacology risk | What strong review should test | Why reviewers push back fast |
|---|---|---|
Potency is presented without enough context | Whether the dose-response evidence is complete and interpretable | One attractive curve does not establish real pharmacology |
Selectivity posture is weak | Whether the paper rules out obvious off-target or assay-artifact explanations | Reviewers quickly distrust compounds that appear too broad or too convenient |
In vivo work outruns PK understanding | Whether exposure, route, and dosing logic support the efficacy claim | Therapeutic claims collapse if the PK story is underbuilt |
Therapeutic significance is overstated | Whether the manuscript distinguishes activity from actual translational promise | Strong data can still be rejected when the interpretation sounds inflated |
Submit If / Think Twice If
Submit if:
- the core compound claims are anchored in complete dose-response evidence
- counterscreens and selectivity logic are visible enough to build trust
- the in vivo dose and route are justified by exposure rather than convenience
- the paper distinguishes target engagement, efficacy, and therapeutic significance
Think twice if:
- the target journal expects more medicinal-chemistry depth, translational depth, or both
- one missing PK, selectivity, or assay-artifact control would change the whole reviewer read
- the manuscript still treats early pharmacology as if it were already therapeutic proof
- the attractive result depends on one assay family more than a coherent evidence package
Readiness check
Run the scan to see how your manuscript scores on these criteria.
See score, top issues, and what to fix before you submit.
Why this page should improve the decision
Pharmacology manuscripts are especially vulnerable to overinterpretation because the results can look exciting early. Reviewers know this, so they read for the gap between observed activity and defensible therapeutic meaning. If that gap is still wide, the paper is not ready for a selective submission.
That is the real value of pre-submission review here. It should tell the author whether the manuscript already reads as rigorous pharmacology or whether it still needs stronger selectivity, cleaner PK logic, or a narrower claim about what the compound evidence actually shows.
Failure patterns reviewers still punish in pharmacology
Strong pharmacology reviewers are trained to distrust attractive compound stories until the paper rules out the obvious ways the signal could be misleading. That means they are not only reading for whether the molecule "works." They are reading for whether the effect is selective, exposure-supported, and meaningful at the dose being claimed.
This is why pre-submission review is useful even for manuscripts with good looking curves and animal data. The review should expose whether the paper still leans too heavily on one assay family, one concentration range, or one interpretive leap from activity to therapeutic implication.
Use this last check before submission:
- identify the one off-target or assay-artifact explanation a skeptical reviewer would raise first
- ask whether the PK story makes the in vivo efficacy claim look believable rather than convenient
- decide whether the manuscript is really a pharmacology paper, a medicinal chemistry paper, or an early translational story and target the journal accordingly
That last classification step matters more than many authors expect, because the same dataset can look underbuilt or appropriately scoped depending on which editorial lens you ask it to satisfy.
It also helps authors avoid the common mistake of adding more experiments without clarifying what decision those experiments are supposed to unlock for the submission target.
In other words, better submission readiness in pharmacology often comes from sharper evidentiary logic, not just a longer experiment list. That is usually the cheaper and faster correction before submission because it prevents avoidable misreads by editors and reviewers.
Frequently asked questions
Dose-response characterization with EC50 or IC50 values from at least three independent experiments, appropriate vehicle and positive controls, and selectivity data showing that the pharmacological effect is on-target rather than non-specific. Papers about drug candidates need in vitro to in vivo translation evidence: a compound that works in cell culture but has no pharmacokinetic data or in vivo efficacy data is unlikely to pass peer review at Journal of Pharmacology and Experimental Therapeutics or British Journal of Pharmacology without explicit acknowledgment of its limitations as a tool compound.
Missing in vivo validation for claims that go beyond mechanism in cell culture. A paper that establishes a pharmacological mechanism in isolated cells or tissue and then extrapolates to therapeutic relevance without in vivo data is a consistent rejection pattern. Reviewers also flag papers where the therapeutic claims are disproportionate to the model used: a rodent model that does not recapitulate the human disease adequately, or an endpoint that is not translationally relevant. The claim must be calibrated to the model's limitations.
Drug discovery papers need ADME data (absorption, distribution, metabolism, excretion) and selectivity profiling across related targets. Mechanistic papers need rigorous target engagement evidence and genetic or pharmacological validation that the observed effect is through the proposed mechanism. Both types need controls, but the nature of the required controls differs substantially. Drug discovery reviewers are also checking whether the hits could be pan-assay interference compounds (PAINS) that give false-positive results, which requires counterscreening data.
When the paper makes translational claims, when it targets a journal with a mixed pharmacology and clinical readership, or when the experimental evidence combines multiple methods such as electrophysiology, pharmacokinetics, and behavioral endpoints. General pre-submission review will miss pharmacology-specific standards for dose-response documentation, selectivity profiling, and in vivo relevance criteria. A reviewer with pharmacology expertise will identify whether the evidence package is complete enough for the target journal tier and whether any standard validation experiment is conspicuously missing.
Sources
Final step
Find out if this manuscript is ready to submit.
Run the Free Readiness Scan. See score, top issues, and journal-fit signals before you submit.
Anthropic Privacy Partner. Zero-retention manuscript processing.
Where to go next
Supporting reads
Conversion step
Find out if this manuscript is ready to submit.
Anthropic Privacy Partner. Zero-retention manuscript processing.